Literature DB >> 16497824

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.

S Wöhrer1, U Jaeger, K Kletter, A Becherer, A Hauswirth, K Turetschek, M Raderer, M Hoffmann.   

Abstract

BACKGROUND: 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) has become a routine measure for staging and follow-up of patients with aggressive lymphoma. By contrast, its usefulness to visualize indolent lymphomas characterized by a lower cellular turnover has not clearly been defined. We have investigated accuracy and clinical usefulness of 18F-FDG-PET in patients with follicular lymphoma (FL). PATIENTS AND METHODS: A total of 64 patients with FL WHO grade I - III (48, 5, and 11 patients) were imaged at our institution to assess the value of 18F-FDG-PET for imaging of FL of different gradings. A total of 115 scans (48 before therapy and 67 for response assessment after treatment) were performed, and findings were compared to conventional staging including CT-scan of thorax and abdomen, sonography of lymph nodes and bone marrow biopsy.
RESULTS: Overall, 18F-FDG-PET had a sensitivity of 98%, a specificity of 94%, a positive predictive value of 95% and a negative predictive value of 98%. These results were significantly more accurate (P = 0.023) than the conventional radiology studies. There was no significant difference (P = 0.093) in the accuracy between patients with indolent (WHO grade I and II) versus aggressive FL (WHO grade III).
CONCLUSION: 18F-FDG-PET scan is a reliable method for staging and follow up of patients with nodal FL irrespective of tumor grading.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497824     DOI: 10.1093/annonc/mdl014

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  36 in total

Review 1.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

Review 2.  Gastrointestinal follicular lymphoma: review of the literature.

Authors:  Shuji Yamamoto; Hiroshi Nakase; Kouhei Yamashita; Minoru Matsuura; Mariko Takada; Chiharu Kawanami; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2010-01-20       Impact factor: 7.527

Review 3.  FDG PET-CT in follicular lymphoma: a case-based evidence review.

Authors:  Stephen D Smith; Mary Redman; Kieron Dunleavy
Journal:  Blood       Date:  2014-12-19       Impact factor: 22.113

4.  Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone.

Authors:  Sweet Ping Ng; Richard Khor; Mathias Bressel; Michael MacManus; John F Seymour; Rodney J Hicks; Andrew Wirth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-07       Impact factor: 9.236

5.  Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information.

Authors:  Reiko Nakajima; Alison J Moskowitz; Laure Michaud; Audrey Mauguen; Connie Lee Batlevi; Ahmet Dogan; Heiko Schöder
Journal:  Blood Adv       Date:  2020-04-28

6.  Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

Authors:  Connie L Batlevi; Fushen Sha; Anna Alperovich; Ai Ni; Katy Smith; Zhitao Ying; John F Gerecitano; Paul A Hamlin; Steve M Horwitz; Erel Joffe; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Craig H Moskowitz; Ariela Noy; Colette Owens; Lia M Palomba; David Straus; Gottfried von Keudell; Andrew D Zelenetz; Venkatraman E Seshan; Stefano Luminari; Luigi Marcheselli; Massimo Federico; Anas Younes
Journal:  Eur J Cancer       Date:  2020-01-08       Impact factor: 9.162

7.  PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.

Authors:  Christelle Tychyj-Pinel; Fabien Ricard; Michael Fulham; Marion Fournier; Michel Meignan; Thierry Lamy; Pierre Vera; Gilles Salles; Judith Trotman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

8.  Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

Authors:  Ruth Pettengell
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  Usefulness of FDG PET for diagnosis and radiotherapy of the patient with malignant lymphoma involving bone marrow.

Authors:  Takashi Nihashi; Kazumasa Hayasaka; Toshihide Itou; Takashi Sobajima; Rikio Kato; Kengo Ito; Yoshiyuki Ito; Takeo Ishigaki; Shinji Naganawa
Journal:  Radiat Med       Date:  2007-04-27

10.  Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.

Authors:  Gaetano Paone; Emmanuel Itti; Corinne Haioun; Philippe Gaulard; Jehan Dupuis; Chieh Lin; Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.